Podcasts about regulatory

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

In this episode of Medsider Radio, we sat down with Rick Bente, co-founder and CEO of Indomo.Indomo's flagship device, ClearPen, is an investigational at-home corticosteroid injection designed to treat inflammatory acne.Rick has over 20 years of experience as an engineer and operator across medtech and pharma, with leadership roles at Medtronic, Insulet, and YourBio, focused on drug delivery and combination products. He is an inventor on more than 50 patents and has generated over $150 million in investments.In this conversation, Rick discusses how Indomo translated an in-office dermatology procedure into at-home care, why usability had to be engineered rather than trained, how the company decided when to exit stealth mode, and how proof-based milestones shaped its fundraising.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Rick Bente.

Part II of the groundbreaking Talk Ten Tuesday series concludes as Tami McMasters Gomez returns to share the real-world impact of UC Davis Health's neurodiversity coding internship.In this powerful follow-up, Tami moves beyond the vision and into outcomes — workforce transformation, productivity gains, retention success, and the measurable value of inclusive hiring in HIM.This isn't a theory. It's operational innovation in action.If you care about strengthening the coding workforce, expanding talent pipelines, and redefining what excellence looks like in the healthcare revenue cycle, you won't want to miss this conversation.Broadcast segments will also include these instantly recognizable panelists, who will report more news during their segments:• POV: Penny Jefferson, Director of CDI Services at the University of California, Davis Medical Center, will share her point of view during the broadcast.• SDoH Report: Marie Stinebuck, CEO for Phoenix Medical Management, will report on the latest news concerning the social determinants of health (SDoH).• CDI Report: Cheryl Ericson will provide an update on clinical documentation integrity (CDI).• The Coding Report: Christine Geiger will report on the latest coding news.• News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk.

Freight Industry Warning: The February 24 edition of the AgNet News Hour tackled a topic that affects every farmer, processor, retailer, and consumer in California — freight. Hosts Nick Papagni and Josh McGill devoted the program to a candid and urgent conversation with Mark Woods and Jose Nunez of Wildwood Express, who say the state's trucking industry is approaching a critical breaking point. Woods, who operates a 45-truck fleet based in Kings County, laid out the growing list of challenges facing California freight companies: rising fuel costs, increasing insurance premiums, emissions regulations, equipment mandates, licensing issues, and deteriorating road infrastructure. While growers often talk about water, labor, and regulation, Woods emphasized that none of it matters if product can't move. “If you can't get it to market, you're dead in the water,” McGill noted — a reality that applies to almonds, tomatoes, citrus, livestock, and every other commodity grown in the state. Fuel remains one of the largest burdens. California diesel prices run significantly higher than neighboring states, and with refinery closures looming, uncertainty around supply and future pricing adds another layer of stress. Woods warned that rising transportation costs inevitably trickle down to consumers — whether it's the price of produce, meat, or a restaurant meal. Insurance is another major pressure point. Freight companies are investing in advanced safety technology — including AI-powered monitoring systems and in-cab cameras — to reduce accidents and protect drivers. Yet despite those investments, insurance costs continue climbing. Woods said companies are doing everything they can to operate safely and efficiently, but margins remain razor thin. Regulatory complexity compounds the issue. Emissions testing requirements, equipment standards, and licensing enforcement create additional compliance hurdles. Woods expressed concern that smaller operators may not survive under the weight of expanding mandates, particularly as newer truck models become more expensive. The conversation also addressed workforce challenges. While interest in commercial driving remains steady, language requirements and licensing scrutiny are impacting available drivers. Meanwhile, California's poor road conditions accelerate wear and tear on already costly equipment. Papagni underscored a critical point: everything in your home — from food to furniture — was delivered by truck. Freight is not optional. It is foundational. As Woods put it, the trucking industry isn't asking for special treatment — just a level playing field and practical policies that allow companies to remain profitable while serving California agriculture. Part two of the freight discussion continues tomorrow.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Send a textWhat if one of the biggest sources of diagnostic variability in prostate cancer isn't the pathologist—but the stain we've trusted for decades?In this episode, I speak with Professor Ingied Carlbom, founder of CADESS.AI, about a different way to approach prostate cancer grading—by rethinking staining, segmentation, and AI decision support from the ground up. We explore why 30–40% interobserver variability persists in Gleason grading and how optimized stains combined with explainable AI can significantly reduce that uncertainty.Ingred shares her journey from applied mathematics and computer science into pathology, the skepticism she faced in 2008, and why CADESS.AI chose not to “optimize H&E,” but instead developed a Picrosirius red + hematoxylin stain designed specifically for computational pathology. We discuss how grading at the gland and cellular level improves reproducibility, why explainability matters for trust, and what it really takes to build both stain and software as a single diagnostic workflow.This conversation challenges long-held assumptions—and asks whether improving data quality should come before building smarter algorithms.Highlights:[00:00–01:08] The problem: 30–40% disagreement in prostate cancer grading[01:08–03:03] Ingrid's path from applied math to digital pathology[03:03–04:58] Early skepticism toward AI in pathology and fear of replacement[04:58–08:56] Why H&E limits segmentation—and how a new stain changes that[10:55–15:09] Clinical testing: non-inferiority, AI assistance, and NCCN risk stratification[19:47–22:59] Explainable UI: color-coded glands and pathologist override[26:16–27:29] Why grading glands (not whole slides) reduces variability[38:09–41:47] Regulatory challenges of combined stain + AI devices[45:52–48:55] The future of optimized stains in routine pathologyResources from This EpisodeCADESS.AI – Prostate cancer decision support systemNCCN prostate cancer risk stratification guidelinesSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

The following article of the Policy & Economy industry is: “Inside Mexico's Regulatory Thought Process” by Erick Ponce Flores, President, ICAN (Instituto de Cannabis) (AA2419)

How are these abusive teen rehab centers still open? Why are parents still sending their kids there? Can't they be shut down? Maia Szalavitz is an award-winning author and journalist who covers addiction and neuroscience. Her book, Help at Any Cost: How the Troubled-Teen Industry Cons Parents and Hurts Kids, is the first comprehensive look at systemic abuse in “tough love” programs and helped spur Congressional hearings & GAO investigations. In this episode, you'll hear how the abusive teen rehab centers featured in Netflix's The Program & Wayward (think Straight Inc., The Seed, Synanon & wilderness camps) began with tough love doctrine, why you can legally treat kids worse than prisoners, why parents aren't suing & why regulations just don't stick. We also weave in the perspective of struggling parents who feel that the anti-troubled teen industry is hurting their healing efforts.  If you like this episode, you'll also like episode 248: SURVIVING THE TROUBLED TEEN INDUSTRY: SEPARATING IDENTITY FROM EXPERIENCE [REMASTERED] Guest:https://x.com/maiasz https://maiasz.com/ Resources:Boy who was raised as a dog https://a.co/d/0bA3dxmi Pace Center for Girls Pensacola https://www.pacecenter.org/locations/florida/escambia-santa-rosa/ Gulf Coast Kids House https://www.gulfcoastkidshouse.org/ Greenhouse Counseling https://www.ghcpensacola.com/  Host:  https://www.meredithforreal.com/  https://www.instagram.com/meredithforreal/ meredith@meredithforreal.comhttps://www.youtube.com/meredithforreal  https://www.facebook.com/meredithforrealthecuriousintrovert  Sponsors: https://www.jordanharbinger.com/starterpacks/ https://www.historicpensacola.org/about-us/  02:00 — The cult origins: Synanon begins04:00 — “I must have needed that” psychology05:00 — The rattlesnake assassination attempt07:00 — The Seed and brainwashing teens08:00 — Straight Incorporated goes national10:00 — Why parents don't believe abuse reports12:00 — Utah wilderness programs rise13:00 — The death of Aaron Bacon14:00 — Moral panic & religious fear15:00 — Good parents, fatal decisions16:00 — Why regulation keeps failing17:00 — Regulatory capture in Utah20:00 — Unannounced inspections change everything22:00 — Why traumatized kids need gentleness27:00 — Warehouses of neglect28:00 — Should therapy have an FDA?29:00 — Renaming punishment as treatment32:00 — Exhausted parents & marketing fear34:00 — How small power corrupts42:00 — Why lawsuits rarely succeed44:00 — Private right of action explained45:00 — Does awareness help or hurt?46:00 — Educational consultants & kickbacks54:00 — Local resources for struggling families55:00 — Undoing drugs & keeping people aliveRequest to join my private Facebook Group, MFR Curious Insiders https://www.facebook.com/share/g/1BAt3bpwJC/

Prior authorizations among Medicare Advantage plans have drawn criticism and concern from patients, providers, lawmakers, and regulators. But hospitals and doctors are uniquely positioned to advocate for their patients' access to and coverage for care. What's necessary is the need to understand the rules of the process. And Medicare Advantage plans have many of them.During the next live edition of the venerable Monitor Monday, the Internet broadcast, Richelle Marting, a healthcare attorney, and certified coder, will help you understand when and how Medicare Advantage plans can use prior authorizations for the critical protections you need to know to advocate for patient care.Broadcast segments will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Matthew Albright of Zelis, will report on current healthcare legislation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

BACK on Air is the podcast for operators who have compliance on their mind and road transport at the heart of their business.This episode is a recording of our recent live webinar, where our legal experts explored the key corporate, employment and regulatory developments set to shape 2026.As we move into the Year of the Horse – a symbol of strength, endurance and forward momentum – we focus on what operators should be doing now to stay prepared, protected and ahead of the curve.In this episode, we cover:Preparing your business for a potential sale and what to expect during the due diligence processGetting your “house in order” so you're ready when opportunity arisesThe key changes under the Employment Rights Act and what the implementation roadmap means for operatorsWhat might trigger a Public Inquiry – including management information, roadside encounters and MOT failuresPractical steps you can take now to influence outcomes and strengthen your compliance positionWhether you're planning for growth, considering your long-term future, or simply want to make sure your business is ready for increased scrutiny, this episode provides clear, practical guidance you can act on straight away.If you'd like to join one of our live webinars – where you can ask questions and take part in interactive polls – you can register here:https://backhousejones.co.uk/free-webinar/This podcast is correct at the time of broadcast and is not a substitute for tailored legal or compliance advice. If you need specific guidance, please seek professional support.BACK on Air is the podcast for operators who have compliance on their mind and road transport at the heart of their business.Enjoyed the episode? Leave us a review and let us know what you'd like us to cover next.Contact: marketing@backhouses.co.ukWebsite: www.backhousejones.co.uk

In this episode of the FinTech Times News and Views podcast, Mark Walker interviews Samantha Yap, founder of Yap Global, at Abu Dhabi Finance Week. They discuss the explosive growth of digital assets and Web3, the role of stablecoins in cross-border payments, and the regulatory environment in the UAE.TakeawaysBitcoin hit all-time highs, indicating explosive industry growth.Stablecoins are becoming essential for cross-border payments.FinTechs are bridging crypto and traditional finance worlds.UAE offers a favorable tax environment for crypto companies.Regulatory clarity in the UAE attracts global crypto players.Yap Global focuses on the evolving crypto story.Stablecoins offer instant payments, beneficial for service providers.Klarna's stablecoin launch could drive mainstream adoption.Multiple stablecoins for different currencies are expected.Amazon might soon accept stablecoin payments.Sound bitesBitcoin hit all-time highs.Stablecoins are essential for payments.UAE's favorable tax for crypto.Regulatory clarity attracts players.Yap Global on crypto evolution.Instant payments with stablecoins.Klarna's stablecoin launch impact.Multiple stablecoins expected.Amazon's potential stablecoin use.Crypto and traditional finance merge.Chapters00:00:00 Introduction to FinTech Times00:01:00 Samantha Yap on Digital Assets00:03:00 Trends in Crypto and Web300:05:00 Stablecoins and Cross-Border Payments00:07:00 UAE's Regulatory Environment00:09:00 Yap Global's Crypto Journey00:11:00 Future of Stablecoins The Fintech Times News &Views Podcast delivers strategic insight into the trends redefining global financial services, with commentary from industry leaders and innovators. Discover more coverage, interviews, research, and partnership opportunities at thefintechtimes.com and follow The Fintech Times across all major social platforms.

Anthony Scaramucci is the founder and managing partner of SkyBridge Capital and a longtime macro investor at the intersection of traditional finance, crypto, and politics. This conversation was recorded live at Bitcoin Investor Week in New York. In this conversation, Scaramucci shares his candid views on Trump, crypto regulation, why the Clarity Act is critical for the industry, SkyBridge's shift toward bitcoin, his early role in the BlackRock Bitcoin ETF, and why progress in Washington requires compromise. He also explains how demographics, regulation, and capital allocation shape bitcoin's long-term future.======================This podcast is sponsored by Abra.com. Abra is the secure way to access crypto and crypto based yield and loan products through a separately managed account structure.Learn more at ⁠http://www.abra.com⁠.======================⁠BitcoinIRA⁠: Buy, sell, and swap 80+ cryptocurrencies in your retirement account. Take 3 minutes to open your account & get connected to a team of IRA specialists that will guide you through every step of the process. Go to ⁠https://bitcoinira.com/pomp/⁠ to earn up to $1,000 in rewards.======================As markets shift, headlines break, and interest rates swing, one thing stays true — opportunity is everywhere. At Arch Public, we help you do more than just buy and hold. Yes, our dynamic accumulation algorithms are built for long-term investors… but where we really shine? Our arbitrage algos — designed to farm volatility and turbocharge your core positions. The best part of Arch Public's products is they are free! Yes, you heard that right, try Arch Public for free! Take advantage of wild moves in assets like $SOL, $SUI, and $DOGE, and use them to stack more Bitcoin — completely hands-free. Arch Public is already a preferred partner with Coinbase, Kraken, Gemini, and Robinhood, and our team is here to help you build smarter in any market. Visit Arch Public today, at ⁠https://www.archpublic.com⁠, your portfolio will thank you.======================0:00 - Intro0:20 - Trump, politics & crypto context4:12 - Why crypto regulation will pass7:45 - Inside the BlackRock bitcoin ETF origin story11:52 - SkyBridge's pivot to bitcoin 18:17 - Biggest risk to bitcoin: demographics & old money20:38 - Scaramucci's politics podcast & final thoughts

In this episode, Elliot Berman and John Byrne break down the major developments from the February FATF Plenary, including Kuwait and Papua New Guinea joining the Grey List and updates on evaluations for Austria, Italy, and Singapore. They also explore FATF leadership changes and the reiteration of Russia's suspension. The conversation moves into rising crypto-enabled human trafficking networks highlighted in a new report from Chainalysis, Cambodia's large-scale crackdown on fraud centers, and several key U.S. regulatory updates. These include FinCEN's new CDD “exceptive relief,” the rollout of a whistleblower portal, and the OCC's proposed changes to the bank appeals process. Elliot and John also discuss recent law enforcement actions, Supreme Court efforts to strengthen conflict-of-interest checks, and a Federal Reserve governor's insight into how AI may reshape the labor market.

AAF President Douglas Holtz-Eakin, Director of Regulatory Policy Dan Goldbeck, and Director of Health Care Policy Michael Baker join us to discuss the latest on the economy, Trump's regulatory agenda, and health policy. Apple: podcasts.apple.com/us/podcast/the-…st/id1462191777 Spotify: open.spotify.com/show/7aWwYw3EKPmTqLQMbRGR2e

Introduction In this episode of the Insurtech Leadership Podcast, host Josh Hollander sits down with Gemma Ros, CTO at The Zebra, to unpack their 2026 State of Auto Insurance Report. They explore what's driving premium divergence across states, how affordability pressure is reshaping consumer behavior, and where regulation, loss costs, and distribution dynamics collide. Guest Bio Gemma Ros is CTO at The Zebra, one of the largest insurance comparison platforms in the United States. Born in Spain, Gemma built her career across engineering and data roles before joining The Zebra, where she leads the technology organization responsible for data infrastructure, product engineering, and AI capabilities. She brings a unique perspective as both a technologist and an insurance industry insider who sees real-time consumer shopping behavior at scale. Key Topics • State-by-state premium divergence — Auto insurance premiums are not stabilizing uniformly. Regulatory environments, loss cost trends, and competitive dynamics are creating vastly different realities depending on where you live. • Affordability pressure and coverage erosion — Consumers facing higher premiums are choosing higher deductibles, lower coverages, and state minimums — creating knock-on effects for uninsured/underinsured motorist exposure across the market. • Carrier growth signals in ad spending — When carriers increase advertising, it signals growth appetite and competitive pricing — a cue for consumers to reshop their policies. • Rate filing dynamics — New rates are being filed and going into effect daily, making the market a moving target for both consumers and distribution partners. • Telematics and ADAS impact on underwriting — Usage-based insurance and advanced driver assistance systems are beginning to reshape how risk is priced, though widespread impact is still unfolding. • Autonomous vehicles and insurance implications — The shift from driver liability to product/manufacturer liability as autonomy scales, and what that means for carriers. • Taking AI from fun to material impact — Gemma's 2026 engineering theme: moving AI adoption from experimental to scalable, repeatable, and operationalized across the entire engineering organization. Quotes • "It's never a bad idea to shop around. Educate yourself — you might be leaving money on the table." • "If you start seeing a lot more ads for insurance companies on TV or on podcasts, that's a good time to reshop — the carriers are signaling they want to grow." • "My main theme for 2026 is taking AI from fun to material impact." Resources • The Zebra's 2026 State of Auto Insurance Report: Available at thezebra.com • The Zebra: thezebra.com — insurance comparison platform Subscribe & Review If you enjoyed this episode, subscribe to the Insurtech Leadership Podcast on YouTube, Apple Podcasts, Spotify, or wherever you listen. Leave a review — it helps other insurance and technology professionals find the show.

Leadership quality and organisational culture are emerging as nearly equal priorities to compensation when professionals choose and stay with employers, according to the Cpl Salary Guide for Ireland 2026. The findings reveal a fundamental shift in talent priorities, as employees increasingly evaluate opportunities based on values, work environment, and leadership behaviours alongside financial rewards. The key findings from this year's report are as follows: While compensation and benefits remain the top priority at 35%, leadership and culture follow closely at 24% as the most important factor when choosing an employer. When examining both first and second most important factors combined, leadership and culture reaches 54% (24% first choice, 30% second choice), narrowing the gap with compensation and benefits at 62% (35% first choice, 27% second choice). Within the leadership and culture category, employees prioritise culture, values and ethics (27%), work environment (25%), and leadership behaviours (24%). Cpl's findings reinforce that leadership quality remains a critical driver of employee attrition. Flexible Working: The Essential Benefit Flexible working arrangements have evolved from a perk to a critical component of employee packages. After remuneration (32%), flexible working ranks as the second most important compensation and benefit factor at 26%. The research shows that 70% of employees now utilise some form of flexible working, with previous studies indicating that one in four candidates would not proceed with a job opportunity lacking flexibility. The predominant flexibility model is hybrid working (over 54%), typically with a 3/2 or 2/3 home/office split. However, next-generation arrangements are emerging, with 12% working fully remote and over 7% utilising compressed work weeks. Organisations offering structured, design-led flexible working strategies gain a significant competitive advantage, particularly when recruiting for high-skilled roles where talent is scarce. Work-Life Balance Takes Centre Stage Within employee experience priorities, work-life balance dominates at 40%, followed by meaningful and stimulating work at 21%. While not yet surpassing compensation in importance, work-life balance, when considered alongside flexible working, represents a core pillar of any successful talent strategy. AI Transitions from Specialist to Mainstream Capability Cpl's analysis found that, between 2022 and 2024, AI references in job titles and descriptions increased year-on-year, peaking in 2024. However, 2025 saw a correction as organisations moved beyond experimentation toward strategic implementation. AI demand remains concentrated in IT (55% of AI-related hiring), Life Sciences (17%), and Customer Service (13%). Business Intelligence has emerged as a distinct growth category since 2023, signalling a shift toward insight-led decision-making. Regulatory roles now account for 3% of AI positions, reflecting growing governance requirements. Cpl found that AI is becoming embedded within existing roles rather than creating new specialist positions. By 2024-2025, AI-related roles comprised just 3% of all jobs, yet within those roles, under 50% of job titles still referenced AI. References to AI in job descriptions have doubled compared to job titles, indicating that employers increasingly expect baseline AI literacy as a standard competency rather than a differentiator. Limited Company Growth Signals Workforce Evolution Ireland experienced near-record limited company incorporations in 2025, with approximately 25,000 new companies registered (a 5-6% increase on 2024). This growth reflects layoffs and slower permanent hiring for experienced professionals, prompting many to establish their own businesses providing specialist services across technology, life sciences, and financial services. This trend signals a structural shift toward self-employment, fractional leadership, and contingent workforce models, offering organisa...

Send a textWhat actually needs to be in place before digital pathology can replace the microscope?In this episode of DigiPath Digest, I walk through the 2026 Polish Society of Pathologists guidelines and translate them into practical steps for real pathology labs. This isn't theory. It's about hardware fidelity, data integrity, validation, and AI integration — and what each of these actually requires in daily workflow.We talk about scanner resolution standards (≤0.26 μm per pixel), 4K monitor calibration, visually lossless compression (20:1), scalable storage, pathologist-driven validation, and what “non-inferiority” truly means.Digital pathology is not just a change of medium. It's an operational shift.Episode Highlights[00:02] Community & growth 1,600+ new newsletter subscribers, 10,000+ Facebook members, and free Digital Pathology 101 book access.[07:20] The 4 pillars of adoption Hardware fidelity · Data integrity · Clinical validation · Future integration.[08:30] Hardware requirements 40x equivalent scanning (≤0.26 μm/px), 4K monitors, >300 cd/m² luminance, 10-bit color depth.[12:00] Workflow & throughput 200–300 slides/day per scanner, automated focus control, urgent case prioritization.[17:25] Storage & archiving ~1 GB per slide. Active archive (6–24 months). Long-term retention (10–20 years). GDPR compliance & TLS encryption.[23:09] Validation philosophy Pathologist-centered validation. Two phases: • Familiarization (~20 retrospective cases) • Dual review with discrepancy tracking Goal: digital must be non-inferior to glass.[29:03] AI in digital pathology AI supports quantification (Ki-67, HER2, ER/PR, PD-L1), tumor detection, and future multimodal predictions — but pathologists remain central.[33:26] Intraoperative telepathology

In Software as a Medical Device (SaMD), defect management is far more than tracking bugs. It is a structured, risk-driven process that directly impacts patient safety, regulatory compliance, and product lifecycle control.This article (and podcast episode) explores both foundational and advanced perspectives on defect management in regulated software environments.We cover:Understanding Defects in SaMD• What defines a defect in a regulated context• How defect management differs from non-medical software• The relationship between defects, risk management, and ISO 14971Building a Compliant Defect Management Process• Essential documentation and tools• Severity and priority categorization• Handling defects discovered during validation or post-market• Differentiating between defects, change requests, and requirement gapsAdvanced & Real-World Scenarios• Managing safety-critical defects• When CAPA or vigilance reporting is required• Handling SOUP and third-party component issues• Ensuring traceability across versions and product variants• Agile defect management strategiesAudit Perspective & Common Pitfalls• Frequent gaps identified by regulators and notified bodies• How defect trend data supports CAPA and management review• Practical advice for startups implementing lightweight but compliant systemsWe also discuss how modern eQMS platforms (such as SmartEye) can help streamline documentation, automate traceability, and improve oversight without adding unnecessary bureaucracy.Defect management in SaMD is not about documentation — it's about maintaining control over risk and ensuring safe, effective software throughout its lifecycle.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkSimon Foeger Linkedin: https://www.linkedin.com/in/simonfoeger/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is powered by Podcastics, the easiest platform to create and publish your podcast.

Brian Whorley, Founder and CEO of Paytient, is rebuilding healthcare's broken payment infrastructure. Paytient enables employers and insurers to front healthcare costs for members who repay over time, interest-free. The company now serves 6,000 employers and powers payment solutions for nearly half of America's 50 million Medicare seniors. In this episode of BUILDERS, Brian reveals his counterintuitive GTM pivot from employers to insurers, why he testified before Congress on healthcare affordability, and how to build in highly regulated markets without fighting the system. Topics Discussed: Why healthcare lacks functional buyer-seller dynamics and transparent pricing The World War II tax quirk that prevents employers from giving healthcare dollars directly to employees Cash market case studies: Why LASIK prices decreased in real terms since 1998 while maintaining quality improvements Paytient's unexpected discovery that insurers were better strategic partners than employers Congressional testimony before the House Committee of Oversight and Government Reform on December 10th The company's evolution from founder-led employer sales to insurance-first distribution strategy Launching self-serve for sub-200 employee companies while closing Fortune 100 accounts How Medicare regulations requiring prescription payment flexibility created a 50-million-person market GTM Lessons For B2B Founders: Test enterprise distribution earlier than your assumptions suggest: Brian assumed Paytient needed a million users before insurers would engage. Instead, one of the nation's largest insurers partnered early because they recognized out-of-pocket costs as a critical experience gap they couldn't solve internally. The insurer's product team understood the problem but lacked control over member finances. When building in complex ecosystems, large strategic partners may engage earlier than expected if you solve a problem outside their core capabilities. Prioritize partners with longer planning horizons: Brian discovered insurers planning 2027-2029 health plans in early 2025, while employers focused on last month's challenges. This planning horizon difference fundamentally changed Paytient's GTM strategy. Insurers became the majority of their business because they could "invest and reshape for the long term" as part of broader strategy. When choosing between customer segments, prioritize buyers who think strategically over those managing tactical, short-term needs—they'll invest in solutions before acute pain points emerge. Regulatory tailwinds can create massive distribution overnight: A law passed four years after Paytient launched required all Medicare insurers to offer exactly what Paytient provides—prescription cost flexibility with insurer-fronted payments. This regulation instantly created a 50-million-person addressable market. Brian now powers this for "almost half the country." When building in regulated industries, track pending legislation that could mandate your solution category, creating instant distribution through compliance requirements. Build different GTM engines for concentrated vs. fragmented markets: Healthcare is "a very concentrated industry" at the top 40 insurers, where Paytient focuses enterprise efforts. For the fragmented small business market (under 200 employees), they launched a self-serve platform at patient.com this month, immediately gaining traction with venture-backed employers seeking simple subscriptions. The dual-motion approach—high-touch for concentrated markets, self-serve for long-tail—maximizes coverage without burning capital on inefficient sales motions. In trust-based sales, delivery quality drives expansion velocity: When Paytient launches with a Fortune 100, "tens of thousands of people have access to patient now." The benefits stack is "sacred and sacrosanct"—a trust-based, relationship-driven sale. Brian emphasizes the product must work "exactly how you said, even better" because performance creates referrals through benefit brokers and consultants. In high-stakes enterprise deployments, your product quality directly determines sales velocity through partner and customer networks. Navigate regulatory constraints as creative boundaries, not barriers: Brian's core advice for healthcare founders: "You have to work with the system as it is." Many founders approach healthcare "as antagonist" with solutions "too foreign or too different" that threaten the status quo. Instead, innovate within existing regulatory and operational frameworks. There are "plenty of space" and "data requirements for how healthcare can work today" to build billion-dollar businesses while respecting industry structure. Fighting the system guarantees slow adoption; working within it enables scale. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

In this episode, we explore how artificial intelligence is revolutionizing HR, with a focus on building trust through data privacy and security. Join us as we discuss practical steps, emerging challenges, and the evolving role of HR professionals in the AI era. Key Topics: The importance of foundational data quality before implementing AI in HR Securing sensitive employee data and managing privacy concerns The role of semantic layers and data organization for effective AI use How AI impacts HR workflows and transforms knowledge work Practical approaches to integrating AI responsibly and securely Education needs for HR to understand AI risks and opportunities Future trends: AI's potential to reinvent HR practices, not just automate Resources & Links: Fuel 50 - Workforce Mobility and Talent Pipelines Amazon - Book: Data Privacy and Security in the Cloud Flurry - Official Website Amazon Bedrock - AI Model Service Anthropic - AI Safety and Privacy Guarantees OpenAI - Responsible AI Use Connect with Brian Platts: LinkedIn Twitter Timestamps:  00:30 - Welcome and introduction to the episode 01:15 - Brian Platts' background in HR and software 02:08 - Flurry's mission to make data meaningful for HR 03:26 - Fun fact: starting career driving a semi truck 04:44 - AI in HR: privacy, security, and data foundations 05:53 - Preparing your HR data for AI adoption 06:08 - Challenges with data quality and use cases 07:08 - Security considerations: private vs. public data 08:22 - Trusting AI vendors and data-sharing risks 09:15 - Teaching AI to query data securely 10:07 - Data organization and semantic layers 11:29 - Improving chatbots and avoiding misinformation 12:26 - Ensuring process accuracy and data integrity 13:14 - Sharing vs. protecting employee data 14:05 - Re-implementing permissions in AI-driven systems 15:01 - Education and awareness around AI security 16:13 - Learning from SaaS security issues during early cloud adoption 17:18 - HR's role in AI education and safeguarding IP 18:14 - Balancing productivity gains with security controls 19:06 - AI's impact on HR future: automation and new workforce roles 20:16 - The concept of the “Meat Layer” and human-AI collaboration 21:02 - Will AI replace HR jobs or empower them? 22:16 - The limits of current AI technology and future innovations 23:03 - Analogies: AI as a horse and the importance of tooling 24:06 - Embracing AI to enhance human work rather than replace it 25:16 - Reinventing HR processes beyond IT-led automation 26:18 - Regulatory challenges and incremental HR AI adoption 27:30 - How HR can lead responsible AI integration 28:03 - Final advice for HR professionals: think broadly and connect the dots

A presidential handoff at noon on January 20 triggered an abrupt reversal across federal policymaking, with agencies shifting from one set of priorities to another almost instantaneously. That whiplash was intensified by a surge of midnight rules on the way out and rapid reversals on the way in, as well as a renewed push by President Trump to expand executive authority. We'll walk through how that turbulence is reshaping regulation with Finn Dobkin and Matias Vesperoni of the George Washington University Regulatory Studies Center. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a wide array of topics, from groundbreaking therapies and strategic corporate moves to regulatory shifts and industry trends shaping the future of healthcare.We begin with Eli Lilly, which is making significant strides with its combined Zepbound and Taltz therapy, showing promising results in the treatment of psoriasis and obesity. This combination therapy, initially successful in psoriatic arthritis, is set to transform treatment protocols by bridging gaps between psoriasis and obesity. This dual-targeting approach highlights a burgeoning trend in the industry: the use of combination therapies to enhance patient outcomes while streamlining treatment regimens. This strategy not only promises better management of interconnected conditions but also reflects a broader industry goal of maximizing therapeutic reach with existing drugs.Novartis is advancing its portfolio with the oral BTK inhibitor, Rhapsido, following a successful Phase 3 trial for a new chronic hives subtype. This development underscores Novartis's commitment to addressing niche markets and unmet medical needs, emphasizing the pharmaceutical industry's focus on expanding the utility of existing drugs. Additionally, Novartis has entered into a notable partnership with Macrocycle Biotech for cardiovascular drug development. This collaboration represents a broader trend where large pharmaceutical companies seek innovative partnerships to expand their therapeutic portfolios through cutting-edge biotech solutions.Meanwhile, Moderna's influenza vaccine submission has been accepted by the FDA after an initial rejection, illustrating a responsive regulatory environment crucial for timely access to vaccines amid potential flu outbreaks.Johnson & Johnson's $1 billion investment plan in the U.S., focusing on cell therapy, aligns with broader industry trends towards personalized medicine and advanced therapeutic approaches. This investment is part of a strategic pivot towards cell and gene therapies that promise to redefine treatment pathways for complex diseases. Similarly, Bayer's $7.25 billion settlement over Roundup litigation shows an industry keen on resolving legal challenges swiftly to refocus efforts on innovation.Regulatory reforms are also gaining attention, with proposals aimed at streamlining FDA processes to enhance drug access and reduce burdens. These reforms could significantly impact drug development timelines and market entry strategies, reflecting an ongoing discourse on balancing regulation with fostering innovation.On a global scale, Stada's €85 million investment in Saudi Arabia points to a strategic move towards enhancing supply chain resilience in the Middle East and North Africa. This aligns with industry trends focusing on regional manufacturing capabilities to ensure drug availability while reducing logistical complexities.A notable example of strategic resource allocation is Eli Lilly's $100 million upfront payment for CSL's IL-6 antibody development rights. This reflects an adaptive approach where initial clinical setbacks are seen as opportunities for new therapeutic ventures rather than dead ends.Turning our attention to Alzheimer's research, Korsana Biosciences has emerged from stealth mode with substantial funding aimed at developing an anti-amyloid antibody capable of crossing the blood-brain barrier. This effort addresses a critical need within Alzheimer's disease treatment—a field marked by intense competition and scientific challenge. Parallelly, IQVIA Biotech highlights the importance of accelerating early-stage interventions for Alzheimer's through data analytics and optimized clinical trials. Such efforts aim to expedite regulatory approvals and bring new therapies to market faster—a trend indicative of leveragSupport the show

Gm! In today's episode we are joined by Kristin Smith to discuss her transition to the Solana Policy Institute, recent U.S. crypto policy shifts, and progress under the Genius Act. We also discuss the CLARITY Act, market structure reform, DeFi and developer protections, institutional adoption, and the importance of durable regulatory clarity. Enjoy! -- Follow Lightspeed: ⁠https://twitter.com/Lightspeedpodhq⁠ Follow Solana Policy Institute: https://x.com/SolanaInstitute Follow Kristin Smith: https://x.com/KristinSmith Follow Danny: https://x.com/defi_kay_ Join the Lightspeed Telegram: ⁠https://t.me/+QHlbNTNS4gc1ZTVh -- Join us at DAS (Digital Asset Summit) in New York City this March!  Use the link below to learn more, and use code LIGHTSPEED200  to get $200 off your ticket! See you there! Learn more + get your ticket here: https://blockworks.co/event/digital-asset-summit-nyc-2026 -- Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ -- Timestamps: (0:00) Introduction (3:01) Kristin Smith's Move to Solana (7:57) Crypto's Regulatory Turning Point (14:59) CLARITY Act & Market Structure (29:37) Protecting DeFi Developers (35:54) Institutional Access to Crypto (40:55) The Path to Lasting U.S. Crypto Clarity (50:49) Closing Comments -- Disclaimers: Lightspeed was kickstarted by a grant from the Solana Foundation. Nothing said on Lightspeed is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Danny, and our guests may hold positions in the companies, funds, or projects discussed.

What if robots could handle tedious retraction, precise bone milling, or even autonomous suturing, freeing surgeons to focus on complex decision-making and more patients?In this episode of the Succeed In Medicine Podcast, Dr. Bradley Block speaks with Dr. Michael Yip, as he explains that today's robots primarily serve as extensions of human surgeons via teleoperation (e.g., da Vinci for precision in hard-to-reach areas), enhancing dexterity, visualization, and accuracy rather than replacing them. He highlights existing autonomous applications in "hard tissue" procedures like the Mako or Stryker robots for precise bone milling in joint replacements, and non-contact examples like CyberKnife for focused radiation therapy.For soft tissue surgery, the more challenging domain due to tissue deformation and variability, autonomy is emerging in simpler, repetitive tasks such as retraction, suctioning, or basic suturing, with demonstrations dating back 15 years but real-world deployment lagging due to engineering, data, and economic hurdles. Dr. Yip discusses why demos in controlled settings don't easily translate to ORs, the shift to data-driven AI (with risks of out-of-distribution failures), and regulatory challenges like FDA expertise gaps and defining probabilistic safety. He predicts stepwise adoption: starting with assistant-level tasks (replacing med student/intern roles in retraction/suction), then progressing to free surgeons for higher-value work, especially in underserved rural areas via telesurgery. Full "skin-to-skin" autonomy (e.g., simple lipoma excision or appendectomy) remains years away, limited by hardware combining strength, dexterity, and precision in one system, though teams of specialized robots could accelerate progress. Ultimately, robotics will alleviate surgeon burnout from growing demand, not eliminate jobs soon.Three Actionable TakeawaysEmbrace Robotics Early in Training: Surgeons and trainees should gain hands-on experience with diverse robotic technologies now, treating them as essential tools that augment precision and dexterity rather than threats to obsolescence.Focus on Repetitive Tasks for Autonomy Gains: Prioritize robotic assistance in tedious, physically demanding steps like retraction, suctioning, or basic closure to free up time, reduce fatigue, and improve efficiency in high-volume or resource-limited settings.Stay Informed on Regulatory and Economic Shifts: Monitor evolving FDA guidelines for AI/surgical autonomy, economic incentives (e.g., cost savings in joint replacements or anastomosis), and liability frameworks to prepare for integration that enhances patient access and outcomes.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Michael Yip is an Associate Professor of Electrical and Computer Engineering at UC San Diego and Director of the Advanced Robotics and Controls Laboratory (ARCLab). His research focuses on surgical robots, biomimetic design, robot learning, autonomous robotic surgery, and deformable tissue manipulation. He has received the NSF CAREER Award, NIH Trailblazer Award, IEEE RAS Distinguished Lecturer recognition, and was named Faculty Innovator of the Year at UCSD in 2024 and elected to the National Academy of Inventors. Previously a Disney researcher at Amazon Robotics, he holds a BSc in Mechatronics Engineering from the University of Waterloo, MS in Electrical Engineering from the University of British Columbia, and PhD in Bioengineering from Stanford University.Website: yip.eng.ucsd.edu and ucsdarclab.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter   This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you're a physician with at least 5 years of experience looking for a flexible, non-clinical, part-time medical-legal consulting role… ...Dr. Armin Feldman's Medical Legal Coaching program will guarantee to add $100K in additional income within 12 months without doing any expert witness work. Any doctor in any specialty can do this work. And if you don't reach that number, he'll work with you for free until you do, guaranteed. How can he make such a bold claim? It's simple, he gets results…  Dr. David exceeded his clinical income without sacrificing time in his full-time position. Dr. Anke retired from her practice while generating the same monthly consulting income.  And Dr. Elliott added meaningful consulting work without lowering his clinical income or job satisfaction. So, if you're a physician with 5+ years of experience and you want to find out exactly how to add $100K in additional consulting income in just 12 months, go to arminfeldman.com.                                                          =============== Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== Regulatory medical writer Dr. Keagen Hadley explains how a pre-med background, clinical research work at a small CRO, and graduate training in occupational therapy led him into a fully remote, high-earning career writing core documents for pharma and biotech. He describes how he first discovered regulatory writing, why it felt like the right balance of science, impact, and flexibility, and how that path allowed him to work, study, and eventually step away from traditional clinical roles. He then outlines what regulatory writers actually do: drafting protocols, investigator brochures, and clinical study reports. And why the work is a strong fit for clinicians who enjoy clear, technical writing and are willing to learn the drug-development process. Along the way, he talks about salary expectations, personality traits that help (discipline, proactivity, comfort with timelines), and the practical steps clinicians can take to move into the field and eventually build their own regulatory writing business. You'll find links mentioned in the episode at nonclinicalphysicians.com/regulatory-medical-writing/

For episode 677 of the BlockHash Podcast, host Brandon Zemp is joined by Parth Kapadia, Co-founder and CEO of OpenVPP.OVPP is Building The Internet of Energy by Providing Regulated Digital Asset Rails for Power & Utility Providers. OpenVPP is led by Co-Founder & CEO, Parth Kapadia. Parth brings a wealth of experience from the electric utility industry, including roles at Exelon Corp and AutoGrid (acquired by Uplight, a Schneider Electric company), where he served as Director of Technical Product Management.

In this episode of Medsider Radio, we sat down with Shaun Bagai, CEO of RenovoRx. The company is developing targeted oncology therapies and is currently commercializing RenovoCath, which is focused on pancreatic cancer. Before joining RenovoRx in 2014, Shaun spent over a decade in the cardiovascular space, including leading global market development at HeartFlow and helping establish the European renal denervation market at Ardian, which Medtronic acquired for approximately $1 billion. He began his career in clinical research and device sales at TransVascular and Medtronic. In this interview, Shaun discusses how testing markets with minimal infrastructure reveals what leads to commercial success, why clinical trial enrollment benefits from sales discipline, and what founders should understand about going public when traditional capital isn't available.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Shaun Bagai.

Once a relic symbolic of earlier times in medicine, the Inpatient-Only (IPO) List has been added to the junkyard of outdated medical processes and practices. And if you and your team fail to plan and align your system appropriately, you risk major financial, operational, and compliance consequences.The good news: during the next live edition of Monitor Mondays, you'll learn why inpatient status is no longer guaranteed by procedure. You'll also learn how the burden of proof for inpatient care now rests in your documentation, along with what you and your team must do to protect appropriate inpatient admissions. Join us when Dr. Stephanie Van Zandt reveals practical strategies to navigate this new landscape and stay ahead of the curve.Broadcast segments will also include these instantly recognizablepanelists, who will report more news during their segments:·      POV: Penny Jefferson, Manager of Coding & Clinical Documentation Integrity Services for the University of Davis Medical Center, will share her point of view during the broadcast.·      CDI Report: Cheryl Ericson will provide an update on clinical documentation integrity (CDI).·      The Coding Report: Christine Geiger will report on the latest coding news.·      News Desk: Juliet Ugarte Hopkins, MD will anchor the Talk Ten Tuesdays News Desk.

A former EPA chief discusses pollution and public health after the Trump administration reverses a landmark federal endangerment rule.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

During CLEAR's recent midyear business meetings in Nashville, we conducted our annual environmental scan, asking committee members to share the top trends, challenges, and policy developments they're seeing across jurisdictions. These environmental scans are consistently cited as one of the most valuable aspects of CLEAR's committee work, offering early insight into emerging issues and practical approaches from colleagues around the globe. In this episode of Regulation Matters: a CLEAR conversation, we highlight key themes from this year's discussions, including the expanding role of artificial intelligence in testing and fraud prevention, legislative and executive pressures on regulatory operations, labor mobility initiatives, internationally trained practitioner pathways, sunrise and sunset review trends, scope of practice expansion, neutrality legislation affecting professional regulation, and evolving approaches to delegation and public protection. Join us as we share insights from regulators and policy leaders across multiple jurisdictions, connecting CLEAR members to the conversations shaping professional regulation in 2026 and beyond. Transcript: http://clearweb.drivehq.com/podcast_transcripts/CLEAR_podcast_episode98_Environmental_Scan_021726_transcript.pdf  

The conversation explores the intersection of Bitcoin mining, AI, and national security, emphasizing the importance of educating policymakers about the benefits of Bitcoin mining for grid resiliency and community engagement. The speakers discuss actionable steps for industry professionals to effectively engage with policymakers, highlighting the need for transparency, collaboration, and proactive communication.TakeawaysBitcoin mining is crucial for national security and grid resiliency.Education is key in engaging with policymakers.Policymakers are increasingly interested in the benefits of Bitcoin mining.Building trust with local communities is essential for Bitcoin operations.The intersection of Bitcoin mining and AI presents new opportunities.Operators should be proactive in addressing concerns of policymakers.Collaboration with trade associations can amplify industry voices.Bringing hardware to meetings can help demystify Bitcoin mining.It's important to focus on community benefits when discussing operations.Engaging with policymakers can be a rewarding experience.Chapters00:00 Introduction to Bitcoin Policy and Experts02:34 Intersection of Bitcoin Mining, AI, and National Security10:07 The Role of Bitcoin Mining in Grid Resiliency16:20 Building Trust with Policymakers23:39 Actionable Steps for Engaging PolicymakersKeywordsBitcoin, policy, mining, AI, national security, grid resiliency, education, engagement, community, trust

Chris Yin is CEO/Co-Founder of Plume Network, the first permissionless, full-stack blockchain built for real-world asset finance (RWAfi). He spearheads the team shaping the infrastructure and policy standards to accelerate the development of onchain capital markets. Chris has an accomplished track record as a founder and investor in the enterprise software space, with tenures at Scale Venture Partners, Rainforest QA, and Xpenser (acquired by Coupa, IPO 2016). In this conversation, we discuss:- Current price action is just short term pain - What to expect from RWAs in 2026 - DeFi opportunities in RWAs - Plume's differentiator - Regulatory developments in RWAs - Optimizing Looping - Onchain asset management - This history of technology - Nest vaults on Solana - Building Key TradFi partnerships - User experience is everything Plume NetworkX: @plumenetworkWebsite: www.plume.orgTelegram: t.me/plumenetwork_communityChris YinX: @chriseyinLinkedIn: Chris Yin---------------------------------------------------------------------------------This episode is brought to you by PrimeXBT.PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.  PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions. Code: CRYPTONEWS50 This promotion is available for a month after activation. Click the link below: PrimeXBT x CRYPTONEWS50FollowApple PodcastsSpotifyAmazon MusicRSS FeedSee All

JFSA's Katsuya Terai on Japan's crypto shift toward FIEA, upcoming disclosure rules, stablecoin pathways, and insider trading plans.

In a January 28 article, Dr. Ronald Hirsch verified that the Centers for Medicare and Medicaid Services (CMS) “has no problem” with the Aetna Severity Payment policy because it “meets the Two-Midnight Rule.” However, there is more to consider than compliance with 42 CFR 412.3. Federal regulations also state Medicare Advantage organizations must comply with Traditional Medicare laws including payment criteria for inpatient admissions at 42 CFR 422.101(b)(2). So the burning question remains: Is CMS disregarding pertinent regulations that could nullify Aetna's policy?During the next live edition of the venerable Monitor Monday, the Internet broadcast, Cheryl Ericson, senior director of clinical policy and education for the Brundage Group, will address this apparent contradiction.Broadcast segments will also include these instantly recognizable features:·      Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. ·      The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. ·      Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.·      Legislative Update: Adam Brenman, legislative affairs liaison for Zelis, will report on current healthcare legislation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Bob Zimmerman covers ESA's fast-tracked Apophis asteroid mission, a commercial attempt to rescue a NASAtelescope, and the contrasting regulatory environments of the UK and New Zealand for space launches.

If one man may legally own another, then he should likewise have the right to disown this property. To deny this right by law involves simultaneously affirming the right of one human to own another as his property but not the right to stop owning another human.Original article: https://mises.org/mises-wire/olaudah-equianos-manumission-regulatory-barriers-freedom

Marc Elovitz is Global Head of Investment Management Regulatory at McDermott Will & Schulte – a leading global law firm. Marc advises private fund managers on running their businesses consistent with all relevant laws, regulations and legal requirements. Marc's cutting-edge work also covers the latest trends of interest to private funds, including blockchain technology and digital assets. He advises on the legal and regulatory considerations involving virtual and digital currency business initiatives and the blockchain technology behind them. In this podcast, we discuss: From Litigation to Regulation The Private Market Boom "Project Crypto" and Regulatory Harmonisation Beyond Digital Gold The Yield Obstacle in Stablecoins Future-Proofing Digital Assets The Trust Factor in Private Equity Solving the AI Explainability Crisis The Delaware Governance Battle Perspective through Fiction

In this episode of Aerospace Unplugged, our host Adam Kress is joined by Pulkit Agrawal, Certification and Regulatory Affairs Leader for Advanced Air Mobility (AAM) at Honeywell Aerospace, and Devin Patterson, Director of Strategic Engagement at Southwest Mission Accelerator Center (MAC). Together, they take a deeper look at the rapidly evolving regulatory landscape that's shaping advanced air mobility, discussing the current progress and challenges, as well as shifting policies across different government levels, and more. Episode HighlightsCurrent Industry Developments, Needs, and Challenges: Explore how Federal Aviation Administration (FAA) initiatives, such as the EIPP program, are enabling early AAM operations, supporting data-driven rulemaking, and influencing collaboration among OEMs, regulators, and regional stakeholders.State of the AAM U.S. Regulatory Landscape: Learn what the U.S. regulatory approach for advanced air mobility is, including an overview of the national AAM strategy and how programs like EIPP fit into the broader effort to scale safe, early operations.Industry Collaborations & Their Significance: Discover how collaboration among industry, municipalities, states, and federal agencies is growing and how it's helping align infrastructure planning, policy development, and community engagement to support AAM deployment.Future Outlook for Advanced Air Mobility: Get a forward-looking view of what to the future may hold as AAM progresses toward broader operations, spanning regulatory frameworks, infrastructure readiness, public acceptance, and more.(No character limit / Highlights)

If one man may legally own another, then he should likewise have the right to disown this property. To deny this right by law involves simultaneously affirming the right of one human to own another as his property but not the right to stop owning another human.Original article: https://mises.org/mises-wire/olaudah-equianos-manumission-regulatory-barriers-freedom

Digital health is no longer in its honeymoon phase. The funding boom is over. AI hype is everywhere. Health systems are overwhelmed. And startups can no longer survive on compelling pitch decks alone. In this episode of Faces of Digital Health, Tjaša Zajc speaks with Ruchi Dass, a former dental surgeon turned public health leader, policy contributor, investor, and advisor to startups scaling across the US, UK, India, Africa, and the Middle East. Ruchi describes a fundamental change in go-to-market (GTM) strategy: Workflow integration is non-negotiable (standalone apps struggle). Reimbursement clarity is critical. Regulatory strategy is part of GTM, not an afterthought. Time stamps: 00:06 – Introduction: startups, global markets, and unconventional careers 01:18 – From dental surgery to global public health and digital health 03:05 – The GTM shift: from promise to proof 04:49 – Staying investable: the four pillars 08:22 – AI ROI: clinical vs operational value 12:17 – Enterprise scaling and “sell to the mindset” 15:05 – Responsible AI: transparency, bias, and lifecycle regulation 19:56 – Predictability vs black-box AI in medicine 22:44 – Global innovation differences: Europe, India, Middle East, Africa 26:21 – Pilotitis: why pilots fail to scale 28:40 – Designing pilots for commercialization 30:26 – Capital flows, geopolitics, and reverse innovation 34:25 – The $1 teleconsultation model in India 37:56 – Digital health and equity: design vs digitization 42:43 – How regulators can keep up with AI 46:03 – Advice for Gen Z and Gen Alpha in digital health 48:50 – Grassroots realities shaping policy Watch the full discussion: https://youtu.be/bmvPzz3Ffp4 www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/

Interview with Nolan Peterson, CEO of Atlas SaltOur previous interview: https://www.cruxinvestor.com/posts/atlas-salt-tsxvsalt-developer-targets-north-americas-30-40-de-icing-salt-supply-gap-8975Recording date: 5th February 2026North America faces a growing crisis in road salt supply that most investors have overlooked. While the US$26 billion global salt market operates largely beneath public awareness, severe winter weather across the northeastern United States and Canada has exposed a structural deficit that has persisted for decades. Atlas Salt (TSXV:SALT) is developing the Great Atlantic Salt Project in western Newfoundland—the continent's first new salt mine in nearly 30 years—to address this critical infrastructure gap.The North American deicing road salt market imports 8-10 million tons annually to meet demand that domestic production cannot satisfy. Existing mines date predominantly from the mid-20th century, with operations beginning between 1906 and 1982. These aging facilities operate at depths of 500-600 meters, often beneath lakes, requiring high operating costs and substantial capital expenditures. Regulatory challenges and thin historical margins have prevented new mine development despite growing demand from population growth, expanded road networks, and increased vehicle numbers.Atlas Salt's competitive advantage stems from its shallow 200-meter deposit depth, which allows access via horizontal drift rather than expensive vertical shaft construction. Located just three kilometers from an existing port facility, the project gains direct access to Atlantic Ocean shipping lanes and the eastern seaboard market. The simplified production process requires only mechanical crushing of 96% grade salt—no chemical processing, tailings, or refining—enabling two-month environmental assessment approval.At full production capacity of 4 million tons annually, Atlas would need to capture only 30-40% of current import volumes, targeting non-cyclical government customers legally mandated to purchase salt for road safety. The market's inelastic demand was demonstrated in January 2026 when Ontario spot prices surged from $65-75 per ton to over $190 during severe winter conditions. CEO Nolan Peterson emphasizes the dual investment appeal: "We are working with lenders who view this as investing into an airport or power plant—something that has long-term sales baked in because you're selling your product to governments, citizens and people."View Atlas Salt's company profile: https://www.cruxinvestor.com/companies/atlas-saltSign up for Crux Investor: https://cruxinvestor.com

Guest: Bob Zimmerman. Musk announces SpaceX will prioritize the Moon before Mars; regulatory approvals for Starship launches are pending, while Voyager Space secures a management contract for ISS operations.1906. WELLS. MARTIAN

In this episode of the Rational Reminder Podcast, we are joined by Theresa Ebden, Vice President of the Investor Office at the Ontario Securities Commission, for a deep dive into how regulators are thinking about modern investor risks—from AI-powered scams to finfluencers and the gamification of investing apps. Theresa explains how the OSC works to protect investors through policy, education, behavioral research, and direct engagement with the public, and why investor education is one of the most powerful tools regulators have. Key Points From This Episode: (0:01:55) Overview of the OSC and why its investor research and education work matters. (5:42) What the Ontario Securities Commission does and its mandate to protect investors and capital markets. (6:25) Inside the OSC Investor Office: policy, education and outreach, and the investor contact centre. (9:28) How the Investor Office identifies priority issues using inquiry data, behavioral insights, and global collaboration. (12:11) The nature of investor inquiries: fraud, crypto confusion, complaints, and recovery room scams. (14:01) How contact-centre data feeds into education, outreach, and policy responses. (16:07) Overview of GetSmarterAboutMoney.ca and its role in investor education. (20:43) Major retail investor risks today: AI-enhanced scams, finfluencers, dark patterns, and gamification. (24:43) What to do if you're impersonated by AI in scam advertisements. (29:28) What a "finfluencer" is and the different categories they fall into. (31:01) Research findings on how strongly finfluencers influence investor decisions. (32:55) Why non-investors are especially vulnerable to finfluencer advice and social-media scams. (36:11) How investors can evaluate online financial advice and check credentials. (38:02) Regulatory challenges in overseeing finfluencers and online financial content. (41:04) How AI magnifies traditional scams and why AI-enhanced fraud is more effective. (43:42) Mitigation strategies: education, just-in-time warnings, and system-level tools. (47:25) Relationship investment scams and why they are especially damaging. (52:53) Research on gamification in investing apps and its effects on investor behavior. (55:25) The Get Smarter About Trading simulator and how it demonstrates gamification effects. (57:19) How gamification can be used positively to improve diversification and outcomes. (58:16) Theresa's perspective on success and her focus on improving the individual investor experience. Links From Today's Episode: Meet with PWL Capital: https://calendly.com/d/3vm-t2j-h3p Rational Reminder on iTunes — https://itunes.apple.com/ca/podcast/the-rational-reminder-podcast/id1426530582. Rational Reminder on Instagram — https://www.instagram.com/rationalreminder/ Rational Reminder on YouTube — https://www.youtube.com/channel/ Benjamin Felix — https://pwlcapital.com/our-team/ Benjamin on X — https://x.com/benjaminwfelix Benjamin on LinkedIn — https://www.linkedin.com/in/benjaminwfelix/ Dan Bortolotti — https://pwlcapital.com/our-team/ Dan Bortolotti on LinkedIn — https://ca.linkedin.com/in/dan-bortolotti-8a482310 Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com)

What do most people regret at the end of their careers? According to legendary venture capitalist Bill Gurley, it's not the failures — it's the risks they never took. In this wide-ranging episode of The Puck, Jim Baer sits down with Gurley — longtime Benchmark partner, early Uber board member, and author of Running Down a Dream — for a candid conversation on boldness, bubbles, AI speculation, venture capital cycles, and America's structural challenges. Gurley reflects on: - Why “boldness regret” weighs heavier than failure - How to turn passion into mastery — and why most people don't - The resume arms race and why young people feel trapped - AI: real revolution or speculative excess? (Hint: both) - Venture capital's evolution — from discipline to burn-at-all-costs - Why five-year AI forecasts may set companies up to stumble - Regulatory capture in healthcare and education - State-by-state competition as America's hidden advantage From Austin's music scene to Silicon Valley's capital cycles, Gurley delivers battle-tested insights from decades at the center of tech's biggest waves. If you care about careers, markets, AI, or the future of the U.S. economy, this episode is essential listening.

In this episode, Harsha Goli from Magnolia Financial discusses the launch of their Bitcoin-enabled banking services across the US, navigating regulatory challenges, and the importance of partnerships with banks. He emphasizes the need for better user experiences in Bitcoin transactions, the role of price oracles, and the implications of the Clarity Act on Bitcoin development. The conversation also touches on the tension between traditional banks and the crypto industry, the future of community banks, and innovations in Bitcoin technology. Harsha shares insights on potential use cases for Magnolia's services and the challenges of bridging the gap in Bitcoin adoption, while also addressing privacy concerns in Bitcoin transactions.Takeaways: